Evidence map›Paper›PMID 26347199›Full record

ArticleDrug design, development and therapy2015

A bioinformatic and mechanistic study elicits the antifibrotic effect of ursolic acid through the attenuation of oxidative stress with the involvement of ERK, PI3K/Akt, and p38 MAPK signaling pathways in human hepatic stellate cells and rat liver.

Wenhua He, Feng Shi, Zhi-Wei Zhou, Bimin Li, Kunhe Zhang, Xinhua Zhang, Canhui Ouyang, Shu-Feng Zhou, Xuan Zhu

Open access · goldAbstract read
In one paragraph

Article in Drug design, development and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 57 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Mutational signatures for breast cancer diagnosis using artificial intelligence.Journal of the Egyptian National Cancer Institute · 2023
    Article
  10. Network Pharmacology and Molecular Docking Reveal the Mechanism ofDrug design, development and therapy · 2023
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Cytotoxic Fractions fromMolecules (Basel, Switzerland) · 2021
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Ursolic acid isolated fromOncology letters · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Wenhua HeDepartment of Gastroenterology, the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.
Feng ShiDepartment of Gastroenterology, the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.
Zhi-Wei ZhouDepartment of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, USA.
Bimin LiDepartment of Gastroenterology, the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.
Kunhe ZhangDepartment of Gastroenterology, the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.
Xinhua ZhangDepartment of Gastroenterology, the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.
Canhui OuyangDepartment of Gastroenterology, the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.
Shu-Feng ZhouDepartment of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL, USA.
Xuan ZhuDepartment of Gastroenterology, the First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.
Nanchang University · CNUniversity of South Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

NADPH oxidases (NOXs) are a predominant mediator of redox homeostasis in hepatic stellate cells (HSCs), and oxidative stress plays an important role in the pathogenesis of liver fibrosis. Ursolic acid (UA) is a pentacyclic triterpenoid with various pharmacological activities, but the molecular targets and underlying mechanisms for its antifibrotic effect in the liver remain elusive. This study aimed to computationally predict the molecular interactome and mechanistically investigate the antifibrotic effect of UA on oxidative stress, with a focus on NOX4 activity and cross-linked signaling pathways in human HSCs and rat liver. Drug-drug interaction via chemical-protein interactome tool, a server that can predict drug-drug interaction via chemical-protein interactome, was used to predict the molecular targets of UA, and Database for Annotation, Visualization, and Integrated Discovery was employed to analyze the signaling pathways of the predicted targets of UA. The bioinformatic data showed that there were 611 molecular proteins possibly interacting with UA and that there were over 49 functional clusters responding to UA. The subsequential benchmarking data showed that UA significantly reduced the accumulation of type I collagen in HSCs in rat liver, increased the expression level of MMP-1, but decreased the expression level of TIMP-1 in HSC-T6 cells. UA also remarkably reduced the gene expression level of type I collagen in HSC-T6 cells. Furthermore, UA remarkably attenuated oxidative stress via negative regulation of NOX4 activity and expression in HSC-T6 cells. The employment of specific chemical inhibitors, SB203580, LY294002, PD98059, and AG490, demonstrated the involvement of ERK, PI3K/Akt, and p38 MAPK signaling pathways in the regulatory effect of UA on NOX4 activity and expression. Collectively, the antifibrotic effect of UA is partially due to the oxidative stress attenuating effect through manipulating NOX4 activity and expression. The results suggest that UA may act as a promising antifibrotic agent. More studies are warranted to evaluate the safety and efficacy of UA in the treatment of liver fibrosis.

Indexed as

Computational BiologyAnimalsAntioxidantsCell LineCell ProliferationCollagen Type IDimethylnitrosamineDose-Response Relationship, DrugExtracellular Signal-Regulated MAP KinasesGene Expression RegulationHepatic Stellate CellsHumansLiverLiver Cirrhosis, ExperimentalMaleMatrix Metalloproteinase 1AntioxidantsCollagen Type IDimethylnitrosamineExtracellular Signal-Regulated MAP KinasesMatrix Metalloproteinase 1MMP1 protein, ratNADPH Oxidase 4NADPH OxidasesNOX4 protein, humanNox4 protein, ratp38 Mitogen-Activated Protein KinasesPhosphatidylinositol 3-KinasePhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsProto-Oncogene Proteins c-aktTIMP1 protein, ratTissue Inhibitor of Metalloproteinase-1TriterpenesUrsolic AcidDAVIDDDI-CPIliver fibrosisNADPH oxidaseROSursolic acid

Identifiers

PMID26347199
PMCPMC4529259
OpenAlexW1959551645

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.